Basit öğe kaydını göster

dc.contributor.authorAytan, Pelin
dc.contributor.authorYeral, Mahmut
dc.contributor.authorGereklioglu, Cigdem
dc.contributor.authorKasar, Mutlu
dc.contributor.authorKorur, Asli
dc.contributor.authorBuyukkurt, Nurhilal
dc.contributor.authorAsma, Suheyl
dc.contributor.authorKozanoglu, Ilknur
dc.contributor.authorOzdogu, Hakan
dc.contributor.authorBoga, Can
dc.date.accessioned2021-04-28T11:57:42Z
dc.date.available2021-04-28T11:57:42Z
dc.date.issued2020
dc.identifier.issn1305-9319en_US
dc.identifier.urihttps://jag.journalagent.com/bakirkoytip/pdfs/BMJ_16_3_248_255.pdf
dc.identifier.urihttp://hdl.handle.net/11727/5796
dc.description.abstractObjective: To present the clinicopathologic features and assess the factors related to the survival in light- chain amyloidosis (AL) patients. Method: All the patients with AL diagnosis being followed-up in the hematology department were recruited in the study. Clinicopathologic data were obtained. Factors related with overall survival (OS) including systemic inflammatory response markers were analyzed. Results: In 16 AL patients, the estimated OS was 58.6 +/- 10.8 months, with a-5-year- survival rate of 52.1%. While, 43.8% of the patients died during the study period. Gastrointestinal and respiratory complaints were the most frequent symptoms. Myocardial and renal biopsies were amyloid positive in 31.3% and 25% of the patients respectively. Myeloma was diagnosed in 18.8% and amyloid was positive in 31.3% of the bone marrow biopsies. There was no difference between surviving and deceased patients with respect to laboratory findings including systemic inflammatory markers. Only immunoglobulin M was significantly lower in the deceased patients and IgM was found to be the only factor independently associated with OS. Lower IgM levels were associated with decreased OS. An IgM value of 75.4 mg/dL was found as a cut-off value with a sensitivity and specificity of 71.4% and 66.7% respectively for the prediction of survival status. Conclusion: AL is a rare, progressive, systemic disease with a wide spectrum of clinical presentations. The disease most commonly presents with gastrointestinal and respiratory complaints. IgM level seems to be an independent predictor of survival and may be used as a prognostic marker.en_US
dc.language.isoengen_US
dc.relation.isversionof10.5222/BMJ.2020.07078en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectlight chain amyloidosisen_US
dc.subjectALen_US
dc.subjectImmunoglobulin Men_US
dc.subjectneutrophil- to- lymphocyte ratioen_US
dc.subjectplatelet -to- lymphocyte ratioen_US
dc.subjectsystemic inflammatory response markersen_US
dc.titleThe Clinicopathologic Features and the Factors Associated with the Survival in Light -Chain Amyloidosis Patients: A Single Center Descriptive Studyen_US
dc.typearticleen_US
dc.relation.journalMEDICAL JOURNAL OF BAKIRKOYen_US
dc.identifier.volume16en_US
dc.identifier.issue3en_US
dc.identifier.startpage248en_US
dc.identifier.endpage255en_US
dc.identifier.wos000576583500009en_US
dc.contributor.orcID0000-0002-5086-5593en_US
dc.contributor.orcID0000-0003-3856-7005en_US
dc.contributor.orcID0000-0002-0895-4787en_US
dc.contributor.orcID0000-0002-8902-1283en_US
dc.contributor.orcID0000-0002-5268-1210en_US
dc.contributor.orcID0000-0002-9680-1958en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.contributor.researcherIDAAD-6222-2021en_US
dc.contributor.researcherIDAAD-5616-2021en_US
dc.contributor.researcherIDAAL-3906-2021en_US
dc.contributor.researcherIDAAE-1457-2021en_US
dc.contributor.researcherIDAAD-5542-2021en_US
dc.contributor.researcherIDAAE-1241-2021en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster